APA (7th ed.) Citation

S, B., AK, C., AC, G., JM, P., DC, M., & MM, W. (2024). Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults. Headache, 64(6), 643. https://doi.org/10.1111/head.14731

Chicago Style (17th ed.) Citation

S, Bodie, Curran AK, Gonzalez-Nelson AC, Perry JM, Manning DC, and Wasilewski MM. "Safety, Tolerability, and Pharmacokinetics of a Single Orally Inhaled Dose of PUR3100, a Dry Powder Formulation of Dihydroergotamine Versus Intravenous Dihydroergotamine: A Phase 1 Randomized, Double-blind Study in Healthy Adults." Headache 64, no. 6 (2024): 643. https://doi.org/10.1111/head.14731.

MLA (9th ed.) Citation

S, Bodie, et al. "Safety, Tolerability, and Pharmacokinetics of a Single Orally Inhaled Dose of PUR3100, a Dry Powder Formulation of Dihydroergotamine Versus Intravenous Dihydroergotamine: A Phase 1 Randomized, Double-blind Study in Healthy Adults." Headache, vol. 64, no. 6, 2024, p. 643, https://doi.org/10.1111/head.14731.